Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-053461

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockF2Sep 7, 2017G500$0.00D271,772ISee footnote
Common stockSep 18, 2017M35,000$0.3025A35,000D
Common stockF5Sep 18, 2017S35,000$67.12D0D
Common stockF6holding———79,082ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F7$0.3025Sep 18, 2017M35,000D—Aug 12, 2019Common stock35,000118,656D

Explanation of responses